A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC).

Trial Profile

A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2012

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms PREST
  • Most Recent Events

    • 30 Jan 2012 Status changed from recruiting to discontinued as reported by EudraCT.
    • 03 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top